What is this medicine used for?
FDA-approved uses
- Attention-deficit/hyperactivity disorder (ADHD) — Children and adolescents aged 6–17; the population with established effectiveness in this US label. ADHD treatment alone or alongside a stimulant, with established US label evidence in children and adolescents aged 6–17.Extended-release oral tablets (Intuniv).
What should I expect?
Improvement in attention and impulsivity develops with regular treatment; MedlinePlus notes that full benefit may take about two weeks. Dose adjustments and individual response can take longer.
Sleepiness or dizziness can appear before useful improvement. Review school, home or work functioning with the prescriber, and report troublesome effects or lack of progress at the agreed follow-up.
How do I take it safely?
Take the ER tablet once daily at the prescribed morning or evening time. Swallow it whole; do not crush, chew or split it. Avoid taking it with a high-fat meal.
Check blood pressure and pulse before treatment, after dose increases and periodically. Report fainting, marked sleepiness or a slow pulse; avoid dehydration and overheating.
Have all medicines checked, especially sedatives, blood-pressure medicines and drugs that change guanfacine levels. Avoid alcohol and driving until you know its effects. Do not combine or exchange ER and immediate-release products yourself.
Do not abruptly stop. A clinician should reduce it gradually and monitor pulse and pressure. Never double a missed dose; after two or more consecutive missed doses, ask before restarting the previous dose. Seek advice if vomiting prevents dosing.
Do not use after a serious guanfacine allergy. Tell the clinician about heart-conduction problems, kidney or liver disease, pregnancy or breastfeeding. Pregnancy evidence is limited; an exposed breastfed infant may need monitoring for sleepiness, feeding problems or a slow pulse.
What side effects should I know about?
- Sleepiness, fatigue, dizziness or low blood pressure.
- Nausea, abdominal discomfort, dry mouth or constipation.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Intuniv: current prescribing information
Which warning signs need help?
- Fainting, extreme sleepiness or a very slow pulse needs urgent assessment.
- Severe headache with confusion, vision changes or chest symptoms after stopping or missing doses may be a dangerous blood-pressure rebound; get emergency assessment.
- Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.
What else should I know to stay safe?
- Do not use after a serious guanfacine allergy. Heart-conduction problems, kidney or liver disease and other medicines that lower blood pressure require review; check pulse and blood pressure before treatment, after increases and periodically.
- Avoid alcohol and unreviewed sedatives; interacting medicines can change guanfacine levels. Avoid dehydration and overheating, and do not drive while impaired. Immediate-release and extended-release products must not be substituted without a prescribing plan.
- Do not stop abruptly. A supervised reduction and blood-pressure monitoring are needed; after two or more consecutive missed doses, ask before restarting the previous dose. Discuss pregnancy and breastfeeding; an exposed infant may need monitoring for sedation, feeding problems or a slow pulse.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- A nonstimulant can still affect the heart: pulse and blood-pressure checks are part of treatment, not just a precaution for people with known heart disease.
- Extended-release and immediate-release tablets deliver guanfacine differently. A familiar ingredient name is not enough to make a safe substitution.
- Vomiting or several missed doses deserves a call. Both restarting and stopping may need a plan because blood pressure can change.
How does it work?
Guanfacine acts at a particular type of receptor, a protein that receives chemical messages in the brain. It activates alpha-2A receptors, which respond to norepinephrine, a messenger also called noradrenaline. The full connection between this action and improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms is not yet understood.
Explore more in Brain & Science: Alpha-2A Signaling: Guanfacine.
How was this medicine developed?
Guanfacine was first approved in the United States in 1986 as a blood-pressure medicine. Intuniv, the extended-release ADHD product, received FDA approval in 2009. The shared ingredient does not make the two formulations interchangeable.
How do I say the name?
Guanfacine: GWAHN-fuh-seen. Capital letters show the stressed syllable.
Medicine forms and official information
Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.
Choose a formulation
Tenex
Guanfacine immediate-release tablets
This is the Tenex label record. The main article covers extended-release guanfacine; a label record does not establish current brand availability.
Official product information: Tenex — U.S. official label (DailyMed)
Extended-release guanfacine tablets
Once-daily ADHD tablets; swallow whole and avoid high-fat meals.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Intuniv: current prescribing information
- Intuniv: FDA approval and supplement history
- Guanfacine: patient medicine information
- Intuniv: FDA label linked by Drugs@FDA
- Intuniv: Package Insert / Prescribing Information / MOA
- Clonidine ER: prescribing information
- Guanfacine: verified parent compound, PubChem CID 3519
- ISMP List of Confused Drug Names
- DailyMed - TENEX- guanfacine hydrochloride tablet
Giving medicine safely to children: family guide (PDF, 3 pages)

